N/A
Completed N=3,281
Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov NCT01990300 ↗Enrolled (actual)
3,281
Serious AEs
0.1%
Results posted
Jan 2019
Primary outcomePrimary: Number of Participants Who Experience at Least One Adverse Events — 206 Participants
Summary
The purpose of this survey is to examine the safety and efficacy of long-term use of alogliptin/pioglitazone(Liovel) combination tablets in patients with type 2 diabetes mellitus determined as warranting combination therapy with alogliptin benzoate and pioglitazone hydrochloride
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Experience at Least One Adverse Events |
206 | — |
| PRIMARY Changes From Baseline in Glycosylated Hemoglobin (HbA1c) |
-0.26; -0.58; -0.66; -0.66; -0.65 | — |
| SECONDARY Changes From Baseline in Fasting Blood Glucose (FBG) |
-14.7; -18.7; -18.4; -19.6; -19.8 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with type 2 diabetes mellitus
Exclusion Criteria
- Patients meeting any of the following criteria will be excluded:
- Patients with current cardiac failure or a past history of cardiac failure
- Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus
- Patients with serious hepatic dysfunction
- Patients with serious renal dysfunction
- Patients with severe infection, pre- or post-operative patients, or patients with serious traumatic injury
- Patients with a history of hypersensitivity to any ingredients of Alogliptin/Pioglitazone
- Pregnant or possibly pregnant women
Data sourced from ClinicalTrials.gov (NCT01990300). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.